A unique and sustained mode of action

FEIBA is a unique composition of coagulation factors1-4

  • Provides both factor II (prothrombin) and factor Xa for rapid and sustained thrombin generation1,2
    • Rapid onset (peak at 15 to 30 minutes) of thrombin generation in an in vitro assay1,2
    • Factor II has demonstrated a prolonged half-life of about 72 hours2
  • Thrombin generation returns to baseline value 8-12 hours after a single dose of FEIBA2
  • Contains additional factors that target multiple sites within the coagulation system to help maintain the coagulation process1,4

Distinct modes of action

  • Restores haemostasis through multiple modes of action, including thrombin generation on the platelet surface1,2,4,5
  • Promotes thrombin generation by mechanisms different from other products and may differ in individual cases—from patient to patient and even from bleed to bleed6-9

Watch the unique mode of action of FEIBA

Download Video: MP4, WebM, Ogg


Disclaimer

Licenses and licensing conditions may vary from country to country. Always consult local prescribing information.

References

  1. 1. Turecek PL, Varadi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia. 2004: 10 (2): 3-9.
  2. 2. Varadi K, Négrier C, Berntorp E, Astermark J, Bordet JC, Morfini M, et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. Journal of Thrombosis and Haemostasis. 2003: 1: 2374-2380.
  3. 3. Turecek PL, Varadi K, Keil B, et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb. 2003;33:16-22.
  4. 4. Varadi K, Montsch P, Keil B, et al. New insights into the role of hemostatic components of FEIBA. Poster presented at the XXII Congress of the International Society on Thrombosis and Haemostasis, Boston, Massachusetts, USA, 2009.
  5. 5. Turecek PL, Varadi K, Gritsch H, et al. Factor Xa and prothrombin: mechanism of action of FEIBA. Vox Sang 1999;77(suppl 1):72-79.
  6. 6. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109(2):546-551.
  7. 7. US National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) Recommendation Regarding the Use of Bypassing Agents in Patients with Hemophilia A or B and Inhibitors. MASAC Document #167. 2006.
  8. 8. Teitel J, Berntorp E, Collins P, D'Oiron R, Ewenstein B, Gomperts E, et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia. 2007:13:256-263.
  9. 9. Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia. 2009;15(1):3-10.

Rapid onset and sustained activity

FEIBA stops bleeds quickly and offers a long dosing interval. Read more

Proven efficacy

Discover the efficacy of FEIBA in both on-demand and prophylaxis treatment. Read more

Integral to inhibitor management

Learn how FEIBA is integral to the management of patients with inhibitors. Read more